Endoscopic Weight Loss Options

Danse Bi; Pichamol Jirapinyo

doi:10.1016/j.ecl.2024.11.002

Endoscopic Weight Loss Options

Endocrinol Metab Clin North Am. 2025 Mar;54(1):149-162. doi: 10.1016/j.ecl.2024.11.002.

Authors

Danse Bi¹, Pichamol Jirapinyo²

Affiliations

¹ Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
² Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: pjirapinyo@bwh.harvard.edu.

PMID: 39919871
DOI: 10.1016/j.ecl.2024.11.002

Abstract

Endoscopic therapies for obesity have emerged as safe, effective, and minimally-invasive alternatives to traditional approaches, including lifestyle modification, anti-obesity medications, and bariatric surgery. Currently, in the United States, 2 types of endoscopic weight loss therapies are Food and Drug Administration (FDA)-approved and are commercially available-intragastric balloons and endoscopic gastric remodeling. These devices and procedures are associated with approximately 10% to 20% total weight loss at 1 year and have distinct technical features, benefits, and risks that providers should be familiar with. This article will focus on the primary FDA-approved endoscopic treatments for obesity and also cover those in development.

Keywords: Bariatric endoscopy; EBMT; EGR; ESG; Endoscopic bariatric and metabolic therapy; Endoscopic gastric remodeling; Endoscopic sleeve gastroplasty; Intragastric balloon.

Publication types

Review

MeSH terms

Bariatric Surgery* / methods
Gastric Balloon
Humans
Obesity* / surgery
Obesity* / therapy
Weight Loss*